Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study
Diabetes Technology & Therapeutics · 2025-05 · 27 (5) · 407-411
DOI: 10.1089/dia.2024.0592 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 01.05.2025. Verfasst von Timothy S Bailey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Headlands Research California-AMCR Institute, Escondido, California, USA. Hauptthemen laut MEDLINE: Blood Glucose Self-Monitoring, Blood Glucose, Diabetes Mellitus, Type 1, Insulin Infusion Systems. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes. Accuracy and adverse events (AEs) were assessed during 14 in-clinic visits comparing CGM and Yellow Springs Instrument reference glucose measurements, including during hyperglycemia and hypoglycemia challenges. In total, 110 participants were implanted with the Eversense 365 CGM System. The overall mean absolute relative difference was 8.8% with primarily one calibration per week. The confirmed alert detection rate at 70 mg/dL was 96.6%, and at 180 mg/dL, it was 97.9%. Ninety percent of the sensors survived 365 days. Interoperable CGM special controls were met. No related serious AEs were reported. The Eversense 365 CGM was shown to be safe and accurate through 1 year with primarily one calibration per week.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headlands Research California-AMCR Institute, Escondido, California, USA.
- Rocky Mountain Research Center, Idaho Falls, Idaho, USA.
- Flourish Inc, San Antonio, Texas, USA.
- Rainer Clinical Research Center, Renton, Washington, USA.
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Elias Emergency University Hospital, Bucharest, Romania.
ORCID-Profile: Timothy S Bailey, Katherine S Tweden
Zitieren
APA
Bailey, T. S., Liljenquist, D. R., Denham, D. S., Brazg, R. L., Ioacara, S., Masciotti, J., Ghosh-Dastidar, S., Tweden, K. S., & Kaufman, F. R. (2025). Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics, 27(5), 407-411. https://doi.org/10.1089/dia.2024.0592
Vancouver
Bailey TS, Liljenquist DR, Denham DS, Brazg RL, Ioacara S, Masciotti J, et al. Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics. 2025;27(5):407-411. doi:10.1089/dia.2024.0592
BibTeX
@article{Bailey2025,
author = {Bailey, Timothy S and Liljenquist, David R and Denham, Douglas S and Brazg, Ronald L and Ioacara, Sorin and Masciotti, James and Ghosh-Dastidar, Samanwoy and Tweden, Katherine S and Kaufman, Francine R},
title = {Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study},
journal = {Diabetes Technology & Therapeutics},
year = {2025},
volume = {27},
number = {5},
pages = {407--411},
doi = {10.1089/dia.2024.0592}
}
EUVIMED